Figure 4.

In vivo efficacy of Fc-engineered antibodies. AG129 mice were challenged with DENV-2, and the antibody, LALA (green) or LALA/KAES (orange), was administered two days after the virus challenge. The viremia was determined on day three (A) and day five (B) after the antibody injection. The variable region of the anti-DENV antibodies used in this experiment was an engineered variant termed 3Cam2, which has improved affinity toward E-proteins of the four DENV serotypes. Each symbol represents one mouse and means ± SD are shown. Asterisks indicate statistical differences compared to the vehicle control group with Dunn’s multiple comparison test for the viremia on days three and five (*, p < 0.05; **, p < 0.01).